Lupin is currently trading at Rs. 825.35, up by 4.45 points or 0.54% from its previous closing of Rs. 820.90 on the BSE.
The scrip opened at Rs. 829.80 and has touched a high and low of Rs. 829.80 and Rs. 815.00 respectively. So far 14935 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 847.35 and Rs. 815.00 respectively. The current market cap of the company is Rs. 37137.96 crore.
The promoters holding in the company stood at 47.00%, while Institutions and Non-Institutions held 37.69% and 15.30% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg to market a generic version of Sunovion Pharmaceuticals, Inc's Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
Lupin's Lurasidone Hydrochloride Tablets is indicated for the treatment of adult patients with schizophrenia, monotherapy treatment of adult patients with major depressive episode associated with bipolar I disorder and adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated bipolar I disorder (bipolar depression).
Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg had annual sales of approximately $3217.3 million in the US (IQVIA MAT September 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
